Table 1.
Patients’ characteristics
| Nb PSMA-11 PET/CTs | Mean | Median | Range | |
|---|---|---|---|---|
| Age at PSMA-11 PET/CT (years) | 1084 | 69.3 | 69.7 | 43–89 |
| Gleason score | 1007 | 7.1 | 7.0 | 4–10 |
| Serum PSA level for PSMA-11 PET/CT (ng/mL) | 1084 | 3.3 | 1.7 | 0.03–112 |
| Delay between the evaluation of FCH PET/CT by thereferring physician and the PSMA-11 PET/CT (days) | 1084 | 45 | 42 | 4–100 |
| Nb PSMA-11 PET/CTs | Proportion | Date of 1st PSMA-11 PET/CTin the cohort | ||
| PET centre | 1084 | |||
| Hôpital Tenon, Paris | 511 | 47% | May 2016 | |
| ICO René Gauducheau, St Herblain | 200 | 19% | July 2017 | |
| Hôpital Lyon Sud | 118 | 11% | July 2017 | |
| CHRU de Brest | 104 | 10% | October 2018 | |
| Centre Jean Perrin, Clermont-Ferrand | 88 | 8% | July 2017 | |
| Centre Léon Bérard, Lyon | 63 | 6% | October 2017 | |
| Gleason score | 1007 | |||
| < 7 | 166 | 16% | ||
| = 7 | 660 | 66% | ||
| > 7 | 181 | 18% | ||
| Initial therapy | 1084 | |||
| Prostatectomy (PX) | 877 | 81% | ||
| Other curative modality | 207 | 19% | ||
| History of PC recurrence | 1084 | |||
| This BCA is the 1st recurrence | 433 | 40% | ||
| Previous recurrence(s) | 651 | 60% | ||
| FCH PET/CT | 1084 | |||
| Negative | 924 | 85% | ||
| Equivocal | 160 | 15% |